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Abstract. 
Despite previous evidence of high level of efficacy, no synthetic metric of yellow fever (YF) vaccine efficacy is 
currently available. Based on the studies identified in a recent systematic review, we conducted a random-effects 
meta-analysis of the serological response associated with YF vaccination. Eleven studies conducted between 
1965 and 2011 representing 4,868 individual observations were included in the meta-analysis. The pooled 
estimate of serological response was 97.5% (95% confidence interval [CI] = 82.9–99.7%). There was evidence 
of between-study heterogeneity (I2 = 89.1%), but this heterogeneity did not appear to be related to study size, 
study design, seroconversion measurement, or definition. Pooled estimates were significantly higher (P < 
0.0001) among studies conducted in nonendemic settings (98.9%, 95% CI = 98.2–99.4%) than among those 
conducted in endemic settings (94.2%, 95% CI = 83.8–98.1%). These results provide background information 
against which to evaluate the efficacy of fractional doses of YF vaccine that may be used in outbreak situations. 
INTRODUCTION 
Yellow fever (YF) is a mosquito-borne viral hemorrhagic fever with a high case-fatality 
ratio. Around 90% of the global burden occurs in Africa, where the disease causes an 
estimated 80,000 deaths annually.1 The ongoing outbreak in Angola with 3,552 suspected and 
875 confirmed cases between December 2015 and July 2016 demonstrates the potential for 
major epidemics and raises fears over global spread to previously unaffected regions.2 
Although no specific treatment exists, a safe and efficacious vaccine is available, which was 
developed in the 1930s and has been widely used since.3 
YF vaccination is recommended for persons  9 months of age, living in or traveling to 
high-risk areas. Based on a recent literature review, the World Health Organization (WHO) 
stated that a single dose of the vaccine is highly immunogenic and confers life-long 
protection against YF.4,5 
The YF vaccine is considered to be highly efficacious, but currently no pooled efficacy 
estimate exists. YF burden estimates and projections need to account for past and future 
vaccination coverage. In the absence of efficacy estimates, these burden estimates usually 
rely on the assumption of total protection after vaccination, with sensitivity analyses of 
limited scope.1 Integrating a pooled estimate of uncertainty around vaccine efficacy would 
help better inform strategic use of the vaccine. In the current situation of global vaccine 
shortage, in the face of a major outbreak, the use of fractional dosing has been approved by 
WHO in principle; however, the evaluation of the short- and long-term efficacy of fractional 
dosing will benefit from a solid understanding of the efficacy of the full dose.Based on a 
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recently published systematic literature review,4 we present a meta-analysis of serological 
response rate associated with the YF vaccine. 
MATERIALS AND METHODS 
Study selection. 
Gotuzzo and others recently published a systematic literature review that informed the 
2013 WHO position paper on the use of YF vaccine.4,5 In this paper, we considered the same 
12 studies conducted between 1965 and 2011 that were published in 11 articles.6–16 
As assessed by Gotuzzo and others, no studies were excluded from the meta-analysis 
based on study design criteria, type of correlate of protection or assay used to measure 
serological response, study quality, or risk of bias. However, Gotuzzo and others identified 
one study that presented a very low serological response rate. As this low level of response 
may be linked to operational failure during the evaluated vaccination campaigns, we 
excluded it from the meta-analysis.7 
Abstract and full texts of the studies were independently read by two of the coauthors to 
classify studies according to study population, seroconversion endpoint, study setting 
(endemic or nonendemic), and study design (interventional, i.e., vaccine was administered 
within the study framework, or observational, i.e., participants were classified based on their 
reported vaccination status). 
Outcome measurement. 
All studies evaluated vaccine efficacy in humans indirectly as the proportion of vaccinees 
that seroconverted using different assays to measure neutralizing antibodies (Table 1). Two 
studies used plaque reduction neutralization tests (PRNTs) with a cutoff for seropositivity 
defined as log neutralization index (LNI)  0.7.9,13 This cutoff was previously reported by 
protection studies in nonhuman primates as the antibody titer required to protect against 
lethal challenge.17 Four studies used positive PRNT test with antibody titer  1:10 as 
seroconversion cutoff.8,10,14,16 This titer is generally considered to be associated with 
protective immunity.4 The remaining studies reported seroconversion endpoints less clearly 
linked with protection. 
Data analysis. 
We used the R package metaphor for analysis.18 Between-study heterogeneity was 
assessed by the Cochran’s Q test and I2 statistic. We combined the results using a random 
effects meta-analysis. Sensitivity analyses were conducted to assess the stability of the pooled 
estimate to inclusion of individual studies as well as the effect of study size and studied 
populations. Asymmetry in the funnel plot was examined visually and tested using Egger’s 
test.19 
Additionally, we conducted a subgroup analyze based on studies using a well-defined 
seroconversion cutoff consensually considered to confer protective immunity.8–10,13,14,16 We 
also stratified individual studies by study design (interventional versus observational) and by 
study setting (endemic versus nonendemic). We used meta-regression to test for subgroup 
differences in serological response rates. 
RESULTS 
The 12 studies analyzed reported serological response rates after vaccination among 15 
different treatment groups, representing a total of 4,868 individual observations (Table 1). 
Across these groups, point estimates ranged from 90 to 100% (Figure 1). 
There was evidence of heterogeneity in serological response between studies (Q test P < 
0.001; I2 = 89.1%). The random effects meta-analysis estimated a pooled efficacy of 97.5% 
(95% confidence interval [CI] = 82.9–99.7%). 
The sensitivity analysis confirmed the stability of the pooled estimate, which ranged from 
97.2% to 97.8% when excluding individual studies. Sample size did not influence the pooled 
estimate strongly. When restricting the analysis to studies with > 150 or > 300 participants, 
the pooled estimates were 97.9% (95% CI = 84.8–99.7%) and 97.7% (95% CI = 84.8–
99.7%), respectively. When restricting the analysis to studies conducted in healthy adults, we 
obtained a pooled estimate of 98.4% (95% CI = 89.1–99.8%). 
Visual inspection of the funnel plot (Supplemental Figure 1) and Egger’s test presented 
evidence of asymmetry (P < 0.0001). 
Subgroup analyses. 
Significant heterogeneity remained when restricting to studies with a seroconversion 
cutoff consensually considered to confer protective immunity (Q test P  0.001; I2 = 89.1%; 
pooled estimate: 98.1%, 95% CI = 79.9–99.8%). Subgroup analysis based on the study 
design criteria yielded similar results, with evidence of heterogeneity in both observational 
and interventional studies (for both groups: Q test P  0.001 and I2 > 80%). Pooled estimates 
were not significantly different between observational and interventional studies (P = 0.283). 
Restricting the analysis to studies conducted in endemic settings or settings at transitional 
risk gave similar results to the main analysis (Q test P < 0.001; I2 = 84.2%; pooled estimate: 
94.2%, 95% CI = 83.8–98.1%). However, studies conducted in nonendemic settings 
exhibited a higher pooled estimate (98.9%, 95% CI = 98.2–99.4%, P < 0.0001) with no 
evidence of heterogeneity (Q test P = 0.467; I2 = 0%). 
DISCUSSION 
Based on studies representing 4,868 individual observations, we estimated a pooled 
serological response rate after vaccination of 97.5%, with 95% CI = 82.9–99.7%. Results 
were similar when restricting the analysis to studies with a seropositivity cutoff consensually 
considered as associated with protective immunity. Thus, this pooled estimate may be a good 
estimate for high protective efficacy of the YF vaccine and is consistent with a previous 
literature review and with the up-to-date WHO position,4,5 while carrying a considerable 
uncertainty which is mostly driven by between-study heterogeneity. 
All studies considered here yielded serological response rates of 90% or more. 
Nonetheless, significant between-study heterogeneity existed, which largely accounts for the 
uncertainty surrounding the pooled response rate. The source of such heterogeneity is not 
obvious. Neither differences in study size, design, or population, nor the chosen endpoint for 
seropositivity satisfactorily explain the heterogeneity in the results. Study setting was the 
only parameter explaining between-study heterogeneity, with studies conducted in 
nonendemic setting exhibiting less heterogeneity than studies conducted in endemic setting or 
settings at transitional risk. 
Lower response rate in endemic settings could be partly explained by a differential 
selection bias. In some of the studies conducted in endemic or low-risk settings, participants 
with preexisting immunity against YF were excluded from the analysis.11,13 Thus, participants 
that were previously exposed to YF but who did not have preexisting immunity, due to a 
weaker immune system, for example, may be slightly more likely to have been included in 
these studies. Heterogeneity in the results of studies conducted in endemic settings may thus 
be linked to heterogeneity in the overall exposure to YF. In contrast, such a selection bias is 
unlikely in nonendemic settings as previous exposure to YF may be exceptional. This 
interpretation would imply that heterogeneity observed in the overall meta-analysis was due 
to study constraints rather than the vaccine itself. 
We observed some evidence of publication bias associated with our results. However, 
sensitivity analysis based on exclusion of individual studies or based on sample size did not 
show a high dependence of our results on any particular study or study size. We thus think 
that publication bias is unlikely to have distorted our results. 
The pooled estimate relied on studies that were mostly conducted among healthy adults. 
Previous evidence suggested weaker immune response in specific groups, such as human 
immunodeficiency virus–infected people or infants.4 Specifically, vaccine efficacy in infants 
and children when coadministered with vaccination against measles, mumps, and rubella, has 
been recently questioned.20 These questions deserve further research effort. 
More than 250 million doses of the YF vaccine have been administered in Africa since 
the 1940s.21 However, no previous study has synthetized the evidence to quantify the efficacy 
based on all available data. In the context of limited resources which holds for most of the 
endemic zone for YF, a summarizing metric of vaccine efficacy, and maybe more 
importantly, a measure of the associated uncertainty, is highly welcome. This may be further 
integrated into vaccine impact evaluation methods and ultimately into the decision process of 
health resource allocation. Furthermore, it also provides background information against 
which to evaluate ongoing investigations of the efficacy of a fractional dose approach that 
may be used in outbreak situations to combat global vaccine shortages.22 
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FIGURE 1. Forest plot of serological response rates after yellow fever vaccination. The diamond delimits the 
95% confidence interval (95% CI) of a fixed effects model. Random effects pooled estimate: 97.5% (95% CI = 
82.9–99.7%). 
TABLE 1 
Studies included in the meta-analysis 
Study Publication 
year 
Study design Study setting Country Vaccine 
assessed 
Manufacturer or 
product 
Vaccine potency Serological 
assay used 
Cutoff used to 
define 
seroconversion 
Differential test 
against other 
flavivirus 
Responders 
/Total 
sample size 
Response 
rate, % (95% 
CI) 
Groot and 
Galvis6 1965 Observational Endemic Colombia 17D† 
French 
neurotropic 
virus 
Not available 
NT test in 
mice 
Not available Not available 282/298 
94.6 (91.5–
96.7) 
Groot and 
Galvis6 1965 Observational Endemic Colombia 17D‡ 
French 
neurotropic 
virus 
Not available 
NT test in 
mice 
Not available Not available 363/387 
93.8 (90.9–
95.8) 
Guerra and 
others*7 
1997 Observational Endemic Brazil 17D 
Oswaldo Cruz 
Institute 
Not available 
NT test in 
mice 
Not available Not available 131/173 
75.7 (68.8–
81.5) 
Reinhardt 
and others8 
1998 Interventional Nonendemic Germany 17D 
Robert Koch-
Institute 
4.7 log10 PFU PRNT NT titer  1:10 Dengue type 1 12/12 
100 (75.8–
100) 
Monath 
and others9 
2002 Interventional Nonendemic 
United 
States 
17D ARILVAX 4.4 log10 PFU PRNT LNI  0.7 
St. Louis 
encephalitis, 
dengue-2, 
Ilheus, and 
West Nile 
279/283 
98.6 (96.4–
99.4) 
17D YF-VAX 5.0 log10 PFU PRNT LNI  0.7 
St. Louis 
encephalitis, 
dengue-2, 
Ilheus, and 
West Nile 
289/291 
99.3 (97.5–
99.8) 
Vazquez 
and 
others10 
2003 Interventional Nonendemic Cuba 17D Not available Not available PRNT NT titer  1:10 
Dengue (4 
serotypes) 
17/17 
100 (81.6–
100) 
Tavares-
Neto and 
others11 
2004 Observational Endemic Brazil 17D Biomanguinhos Not available 
HI 
antibodies 
Not available 
Dengue (4 
serotypes), 
Saint Louis, 
Ilheus, Rocio 
130/145 
89.7 (83.6–
93.6) 
Camacho 
and 
others12 
2004 Interventional Nonendemic Brazil 
17DD§ 
Oswaldo Cruz 
Institute 
 1,000 MLD50 PRNT 
NT titer  630 
mIU/ml 
none 205/209 
98.1 (95.2–
99.3) 
17DD§ 
Oswaldo Cruz 
Institute 
 1,000 MLD50 PRNT 
NT titer  630 
mIU/ml 
none 192/193 
99.5 (97.1–
100) 
17D 
Oswaldo Cruz 
Institute 
 1,000 MLD50 PRNT 
NT titer  630 
mIU/ml 
none 210/211 
99.5 (97.4–
100) 
Belmusto-
Worn and 
others13 
2005 Interventional 
Transitional 
risk 
Peru 
17D ARILVAX 4.4 log10 PFU PRNT LNI  0.7 
Dengue (4 
serotypes) 
619/652 
94.9 (93.0–
96.4) 
17D YF-VAX 5.0 log10 PFU PRNT LNI  0.7 
Dengue (4 
serotypes) 
298/329 
90.6 (86.9–
93.3) 
Pfister and 
others14 
2005 Interventional Nonendemic Switzerland 17D 
Three different 
manufacturers 
4.2 log10 PFU PRNT NT titer  1:10 none 304/304 
100 (98.8–
100) 
Suzano 
and 
others15 
2006 Observational Endemic Brazil 17DD 
Oswaldo Cruz 
Institute 
Not available PRNT 
NT titer  630 
mIU/ml 
none 425/433 
98.2 (96.4–
99.1) 
de Melo 
and 
others16 
2011 Observational Nonendemic Brazil 17DD 
Oswaldo Cruz 
Institute 
6.3 log10 PFU PRNT NT titer  1:20 
Dengue 
(serotype not 
available) 
238/238 
100 (98.4–
100) 
CI = confidence interval; HI = hemagglutination inhibition; LNI = log neutralization index; MLD = minimal lethal dose; NT = neutralization test; PFU = plaque-forming unit; 
PRNT = plaque reduction neutralization test. 
* Not included in the meta-analysis. 
† Subcutaneously or by scarification. 
‡ By scarification. 
§ Different seed lots. 
SUPPLEMENTAL FIGURE 1. Funnel plot, accounting for between-study heterogeneity. (A) All studies, (B) studies conducted in endemic settings or settings at transitional risk, 
and (C) studies conducted in nonendemic settings. Dots represent studies conducted in endemic settings or settings at transitional risk and triangles represent studies 
conducted in nonendemic settings. 
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